Global InformationArven Pharmaceuticals information
Arven Pharmaceuticals is a Turkish pharmaceutical corporation headquartered in Istanbul established as a subsidiary of Toksöz Group in 2013. Arven's primary focus is development and production of high-technology inhaler and biotechnology products. The company is specialized on difficult to make products.[1] Arven is the first Turkish company developing biosimilars for global markets, including the US and EU.[2]
Arven has obtained a marketing authorization in 2016 for the biosimilar of Filgrastim, marketed under Fraven, which is the first biosimilar drug, developed and manufactured from cell to final product in Turkey.[3][4]
Additionally, Arven is the first Turkish company to design and develop a patented Dry Powder Inhaler (DPI) device under Arvohaler trademark and globally introduced Cyplos (salmeterol/fluticasone) product inhaled with Arvohaler device.[5]
Some of the ministry of health foundations have visitations to the company for the vaccine manufacturing potential during COVID-19 pandemic period.[6]
- ^ "Our History - Arven Pharmaceutical".
- ^ "GBR - Zafer Toksoz". Global Business Reports. 2020-03-02. Retrieved 2020-12-21.
- ^ Toksöz Group-Arven
- ^ [1] Türkiye’nin ilk biyobenzer ürününü üretti - Vatan Finans.
- ^ [2]|ARVOHALER Trademark of ARVEN ILAÇ SANAYI VE TICARET ANONIM SIRKETI -
- ^ Aşı üretim merkezlerine yönelik gerçekleştirdiğimiz ziyaret